Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 362

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

A Comparison of Salmeterol with Albuterol in the Treatment of Mild-to-Moderate Asthma

Pearlman, David S., Chervinsky, Paul, LaForce, Craig, Seltzer, James M., Southern, D. Loren, Kemp, James P., Dockhorn, Robert J., Grossman, Jay, Liddle, Roger F., Yancey, Steven W., Cocchetto, David M., Alexander, W. James, van As, Andre·1992·New England Journal of Medicine

Abstract

BACKGROUND: An effective, long-acting bronchodilator could benefit patients with asthma who have symptoms not controlled by antiinflammatory drugs. We compared a new long-acting, inhaled beta 2-adrenoceptor agonist, salmeterol, with a short-acting beta 2-agonist, albuterol, in the treatment of mild-to-moderate asthma. METHODS: We randomly assigned 234 patients (150 male and 84 female patients 12 to 73 years old) to one of three treatment groups: one group received 42 micrograms of salmeterol twice daily, one received 180 micrograms of albuterol four times daily, and one received placebo. Treatment was assigned in a double-blind fashion, and all patients could use supplemental inhaled albuterol as needed during the 12-week treatment period. RESULTS: Measurements of the forced expiratory volume in one second, performed hourly for 12 consecutive hours, showed that a single dose of salmeterol produced a greater mean area under the curve than two doses of albuterol taken 6 hours apart (6.3 vs. 4.9 liter.hr, P < 0.05). The difference was significant on day 1 and at week 4 of the study, but not at week 8 or 12. Salmeterol was also more effective than albuterol or placebo (with albuterol taken as needed) in increasing the morning peak expiratory flow rate: salmeterol induced a mean increase of 24 liters per minute over the pretreatment values, as compared with a decrease of 6 liters per minute with albuterol (P < 0.001) and an increase of 1 liter per minute with placebo (P = 0.002). The mean overall symptom score was improved most by salmeterol treatment (P < 0.05), with the number of days with symptoms and of nights with awakenings decreasing by 22 percent and 52 percent, respectively; there were no differences in results between albuterol treatment and placebo administration. We found no evidence of tolerance to the bronchodilating effects of salmeterol, and adverse reactions to all the treatments were infrequent and mild. CONCLUSIONS: For the management of mild-to-moderate asthma, salmeterol given twice daily is superior to albuterol given either four times daily or as needed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejm199211123272004

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 362

Metadata

Authors
Pearlman, D. S., Chervinsky, P., LaForce, C., Seltzer, J. M., Southern, D. L., Kemp, J. P., Dockhorn, R. J., Grossman, J., Liddle, R. F., Yancey, S. W., Cocchetto, D. M., Alexander, W. J., & van As, A.
Venue
New England Journal of Medicine
Published
1992-11-12
Volume
327
Issue
20
Pages
1420-1425
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2336268573
Cited by
362
References
8
FWCI
11.58
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Comparison of Salmeterol with Albuterol in the Treatment of Mild-to-Moderate Asthma. https://app.cochat.ai/papers/10.1056/nejm199211123272004
The paper
Pearlman, D. S., Chervinsky, P., LaForce, C., Seltzer, J. M., Southern, D. L., Kemp, J. P., Dockhorn, R. J., Grossman, J., Liddle, R. F., Yancey, S. W., Cocchetto, D. M., Alexander, W. J., & van As, A. (1992). A Comparison of Salmeterol with Albuterol in the Treatment of Mild-to-Moderate Asthma. New England Journal of Medicine. https://doi.org/10.1056/nejm199211123272004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.